AzTrials
AzTrials

Celiac DiseaseNCT05204446

Behavioral Intervention for Celiac Disease

A study testing GROW Project and GROW+ Project in people with Celiac Disease, run by Children's National Research Institute at 1 site in United States.

Enrolling by invitation

Enrolling by invitation. The study team selects and invites participants, usually from an existing group of patients.

Sites and contacts
Official record
Search all trials

Trial summary

Celiac disease (CD) is a chronic autoimmune condition whose only currently available treatment is a strict, burdensome gluten-free diet (GFD). The current proposal uses a theory-driven empirical approach for optimizing the GFD for teens and their parents by targeting knowledge, behavior, and coping skills through… Read more about this study

Who is it for?
Ages 12 to 16 years
Conditions the study is for
Celiac Disease
What is being tested?
GROW Project and GROW+ Project
Could I receive a placebo?
No, everyone receives an active treatment
How many people
96 participants
Where
1 siteUnited States
Study dates
7 Jun 2022to 1 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 16 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Teens with a physician- confirmed CD diagnosis and one parent or guardian.
  • Teens 12-16 years at the time of enrollment.
  • Proficient in written and spoken English.
  • Have regular access to a device enabled for video conferencing (Zoom) and receiving SMS messages.

Who cannot join

  • The teen's CD diagnosis is questioned or revoked at any time during the study period;
  • Another member of their household is already enrolled in the study;
  • The teen has a developmental disability or major neuropsychological condition that, in the opinion of the investigators, would impair communication and engagement with the other participants and intervention material.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United States1 site
  • Children's National Hospital

    Washington D.C., District of Columbia, 20010

Other trials in United States

About this study

Official title: Testing a Behavioral Intervention in Pediatric Celiac Disease

Celiac disease (CD) is a chronic autoimmune condition whose only currently available treatment is a strict, burdensome gluten-free diet (GFD). The current proposal uses a theory-driven empirical approach for optimizing the GFD for teens and their parents by targeting knowledge, behavior, and coping skills through educational and cognitive-behavioral techniques. Integration with telehealth and SMS (short message service; "text") technology for delivering the intervention has the potential to reduce barriers to specialized treatment at both early and later stages of implementation. The proposed research will refine and test a behavioral intervention for teens with CD and their parents using an iterative stakeholder-centered design. It will consist of a small pilot randomized control trial (RCT) (n=96 dyads) that will examine the preliminary efficacy of the intervention and its impact on quality of life and GFD management by targeting self-efficacy, illness identity, and food-related activities. This work has the potential to make a lasting impact on the standards of care and available treatments to optimize CD management in youth and their families.

Read the detailed description

Celiac Disease (CD) is an increasingly common disease with significant morbidities if treatment is not achieved. The incidence and prevalence of CD has been increasing in children and teens over the past 15 years in the United States, with prevalence rates nearly tripling from approximately one in 133 to one in fifty children, according to regional population cohort studies. Untreated CD is associated with risks for non-Hodgkin's lymphoma, intestinal cancers, inflammatory bowel disease, diabetes mellitus, and a twofold increase in risks for mortality. The only treatment for CD is a strict Gluten-Free Diet (GFD), which is complex, expensive, tiring, and anxiety-provoking. CD is also associated with impaired quality of life (QOL) and burdensome treatment. Impaired QOL, including poor psychological well-being and functioning, occurs more frequently in CD compared with the general population, likely due to physiological vulnerabilities associated with CD as well as the social impact of the GFD. Teens with CD may experience psychosocial difficulties associated with the GFD due to negative perceptions about reasons for requesting gluten-free foods. Therefore, despite advances in palatable gluten-free products and their availability, youth with CD continue to struggle with GFD management and face new sources of misinformation and misperceptions by others. Like their children, parents are also at risk for poorer QOL resulting from the challenges associated with the treatment of CD in their children. Parents may experience social isolation and stress associated with caring for a child with CD, which can impact family dynamics and the daily tasks of following the GFD. Caregivers who assume responsibility for their children's care report increased depressive symptoms, family stress, and higher burden. According to Social Cognitive Theory, effective support from parents is crucial for successfully managing childhood chronic illnesses and in facilitating the transition to adult medical care, including GFD management. A review of adherence interventions for youth with CD concluded that there is a significant need for evidence-based interventions to support GFD management, and that potential targets should incorporate considerations of the individual, family, community, and health system. The authors also emphasized the promise of novel technologies as a potentially useful and accessible approach for intervention delivery. GIP testing is a promising technology for detecting gluten ingestion, but clinical recommendations and support for GIP testing are needed. GIP testing has demonstrated reliable and valid detection of gluten in relation to histological lesions found via duodenal biopsy as well as high acceptability and feasibility in children and adults. Given the public availability and potential future affordability of GIP test kits, insight into the effects of their use on clinically relevant outcomes is crucial. Additionally, enthusiasm about the potential for accurate biometric assessment of adherence in outcomes research must also be tempered with the possibility that GIP testing may modify behavior and other patient-reported outcomes, with potential benefits or iatrogenic effects. Accordingly, there is an unmet need to counsel patients, particularly teens, on strategies for proactively using at-home GIP tests and optimize outcomes such as QOL and GFD self-management.

The Current Study

The current study is a randomized controlled trial. Participants will total 96 teens (ages 12 to 16 with celiac disease (CD) and their parents or legal guardians (referred to as "parents") who receive medical care from our celiac disease clinics in the Division of Gastroenterology Children's National Hospital (CNH). Dr. Coburn is an integrated member of the Celiac Disease Program Clinical Team, and has met with colleagues, including the gastroenterologist (Dr. Kerzner, Scientific Advisor), nurse, and dietitian, to discuss the proposed study and all team members have expressed their support for this proposal.

After parent-teen dyads have met inclusion criteria, given consent and assent for the RCT, and completed their baseline assessments, the participants will be randomized as dyads into either the "GROW" intervention group, the enhanced "GROW+" intervention group, or the control group. Assignments will be made using block randomization, stratified by the 4 intervention cohorts of 8 dyads each. N=96 parent-teen dyads will be recruited (RCT; 32 in the "GROW" intervention group, 32 in the enhanced "GROW+" intervention group, and 32 in the care-as-usual control group) over the course of the study continuously in cohorts with active recruitment in the investigators' Celiac Disease Clinic as well as through the existing patient database.

Considering the significant challenges faced by teens with celiac disease and their families, there is an urgent need to develop tailored, innovative interventions that are appealing to this age group and potentially efficacious in improving celiac disease-related physiologic and psychosocial functioning. The minimal risks of completing data collection and a 6-week behavioral intervention are reasonable to justify the proposed study, which will minimally provide knowledge on behavioral intervention techniques for teens with CD and their parents and could also lead to improved scientific clarity on the mechanisms that underlie management of special diets in youth. In addition, collection of the psychosocial and clinical data may provide information for health professionals to promote optimal clinical care in youth with celiac disease, with the ultimate goal of reducing risk for long term negative health outcomes. The proposed study has the potential to ultimately result in the availability and implementation of an efficacious intervention for a large community of youth with CD and their families throughout the United States and may have utility in other chronic illness populations as well.

Conditions
Celiac Disease
Being tested
GROW Project, GROW+ Project
Medical subject headings
Celiac Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GROW ProjectBehavioural

    ("GROW" Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week.

  • GROW+ ProjectBehavioural

    ("GROW+" Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention.

Study groups in NCT05204446
Study groupRoleWhat they receive
GROW ProjectExperimental("GROW" Group): Live interactive telehealth-based group meetings will be held for 60 minutes per week over six weeks using Zoom for Telehealth, a HIPAA-compliant platform provided by the PI's institution. A teen group (n=8 per cohort) and a parent group (n=8 per cohort) will be run concurrently but separately, with coordinating topics. Each group meeting will introduce and facilitate discussion of information and CBT-oriented topics for coping and management of CD. Participants will be encouraged to use their audio and video to engage with the interventionist and each other. Between sessions, resources sent through text-based SMS messages using Twilio HIPAA-compliant software 3x/week as reminders of skills and goals for the week.
Receives: Behavioral: GROW Project
Care-As-UsualNo interventionParticipants assigned to the control group (n=32 dyads) will receive care as usual, which consists of appointments in the Celiac Disease Clinic (at diagnosis, 3 months post-diagnosis, 6 months post-diagnosis, and annually after diagnosis thereafter). These appointments consist of a gastrointestinal physician or nurse practitioner, dietitian, GFD educator, and psychologist for 40-minute consultations each.
GROW+ ProjectExperimental("GROW+" Group): Will include the GROW Project with enhanced behavioral strategies and materials identified from phase 2 data (e.g., group discussion about GIP testing, text-based check-ins, etc.) In addition, teens in GROW+ will be encouraged to complete a minimum of 2 GlutenDetect tests per week (12 total) and report results in REDCap (Research Electronic Data Capture, a secure, web-based survey application) throughout the intervention.
Receives: Behavioral: GROW+ Project

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Teen quality of life as measured by Teen and parent-proxy report on PROMIS Pediatric Profile-37

    Anxiety, depressive symptoms, fatigue, pain interference, physical function-mobility, peer relationships, \& pain intensity

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

  2. Parent quality of life as measured by Parent PROMIS Adult Profile-43

    Parent anxiety, depression, fatigue, pain interference, physical function, sleep disturbance, and ability to participate in social roles and activities as well as a single pain intensity item

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

  3. Parent health-related quality of life as measured by Parent report PedsQL 2.0 Family Impact Module

    Parent impact of child health on quality of life

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

  4. Teen celiac disease health-related quality of life as measured by Teen self-report on Celiac Disease Quality of Life (CDLIFE)

    A validated measure of health-related quality of life in children ages 8-18 living with celiac disease in the United States. 22 items rated 1 (never) to 5 (almost always) for a total possible score ranging from 0-88, with a higher score indicating better health-related quality of life.

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

  5. Gluten-Free Diet Management (expert) as measured by Expert GFD Adherence Rating (SDE)

    Structured global rating by gluten-free diet expert based on dietary recall for potential sources of gluten using online GlutenFreeDiet program.

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

  6. Gluten-free diet management as measured by Teen & Parent-report Celiac Dietary Adherence Test

    Survey measure on symptoms and behavior associated with gluten-free diet management

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

  7. Gluten Immunogenic Peptides as measured by GlutenDetect

    At-home Gluten Detective kit to detect gluten ingested within 24 hours in teen's urine or stool. Teens will be prompted via SMS text message and will be given a 24-hour window to complete the test and send a photo of the results.

    Measured: Baseline, Weekly Intervention, Immediately Post-Intervention, 3 Month Follow-Up

  8. Gluten-Free Diet Experiences as assessed by qualitative interview about perceived QOL and GFD management experiences

    Semi-structured qualitative interview about current experiences with GFD management for teen/parent.

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

Secondary outcomes (2)
  1. Self-Efficacy as measured by the Celiac-SE

    25-item validated measure of self-efficacy to adhere to the gluten-free diet. Scores below 7 are considered low self-efficacy and scores below 5 indicate very low self-efficacy expectations.

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

  2. Illness Identity as measured by the Illness Identity Questionnaire

    Four illness identity components: rejection, engulfment, acceptance, and enrichment. Agreement rated on 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree).

    Measured: Baseline, Immediately Post-Intervention, 3 Month Follow-Up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jan 2022
  2. Study start7 Jun 2022
  3. Primary completion1 Oct 2026 (estimated)
  4. Study completion1 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
96 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05204446
Sponsor's protocol ID
Pro00015490
Status last verified
Jul 2025
First submitted
14 Jun 2021
Last updated
11 Jul 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing GROW Project and GROW+ Project in people with Celiac Disease, run by Children's National Research Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: enrolling by invitation, as of the sponsor's last update on 11 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Teen quality of life as measured by Teen and parent-proxy report on PROMIS Pediatric Profile-37 (time frame: Baseline, Immediately Post-Intervention, 3 Month Follow-Up). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in